

Group ID	Animal #	Body Weight	Trim5 Allele*	Time Infected	Peak viremia (RNA copies/ml)
Vaccine	AS72	3.85	RR		
	AZ61	5.5	sR		
	AZ74	5.14	ss	Week 18	5080320
	AV53	4.29	RR		
	BC49	6.06	sR		
	DCA3	4.27	sR	Week 22	2669351
	T4232	5.14	RR		
	7-42	4.95	sR	Week 17	9012954
	7-104	4.31	sR		
	7-152	5.16	sR		
Null	AZ04	4.85	sR	Week 17	1251927
	AZ41	4.86	sR	Week 22	3872290
	AZ60	4.08	sR	Week 15	49553554
	AZ80	4.74	ss	Week 19	229126334
	AZ87	4.11	sR	Week 15	62656944
	AV12	5.81	sR		
	DCJ4	4.3	ss	Week 16	2569070
	T4244	5.16	RR	Week 16	1327513
	7-26	4,74	sR	Week 15	28614920
	7-60	4.88	sR		

*: Trim5 alleles were typed based on the sequences in the SPRY region, R: restrict allele 1-5: Trim5^{TFP}; s: sensitive allele 6-11: Trim5^Q.

Table S1. Monkeys and SIV infection status.




Fig. S1. Anti-CD4 antibodies were not detected in vaccinated monkeys. (A) Purified human CD4 protein was used to coat ELISA plates and anti-CD4 IgG in monkey sera (1:50 dilution) from monkeys in the null or vaccine group at pre-vaccination (Week 0) and post-vaccination (Week 14) were determined. (B) HEK 293 cells transfected with plasmid encoding human CD4 were stained with monkey sera and detected with PE-labeled anti-monkey IgG antibodies. There is no significant difference between null and vaccine monkeys at Week 0 or Week 14 ($p > 0.05$).